GlassScriptPhysician profile
Sonia C Wiggins
NPI 1063676146
$2,714.23
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,251 · 2022: $863 · 2023: $416 · 2024: $39.44 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.65 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $427.83 | 2021-2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $206.43 | 2021-2022 | |
| Dexcom, INC. | $177.82 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $172.71 | 2021-2023 | Mounjaro |
| Abbvie INC. | $119.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $116.97 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $104.49 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.37 | 2021-2023 | Jardiance |
| Abbott Laboratories | $92.94 | 2022 | |
| Ironwood Pharmaceuticals, INC | $89.50 | 2021-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.12 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $82.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $52.16 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $50.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.26 | 2023 | |
| Paratek Pharmaceuticals, INC. | $45.60 | 2022-2023 | Nuzyra |
| Amgen INC. | $30.32 | 2021 | |
| Astellas Pharma US INC | $22.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.63 | 2021 | |
| Pfizer INC. | $15.12 | 2021 | |
| Esperion Therapeutics, INC. | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.